XBiotech Inc. — 2018 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2018. The filing is an annual report, not a standalone fourth-quarter filing; unaudited quarterly data are also disclosed. Filed March 13, 2019. XBiotech is a pre-revenue biopharmaceutical company developing naturally occurring “True Human” monoclonal antibodies, led by bermekimab (MABp1), which targets IL-1α.
Financial and operating performance
| Metric | 2018 | 2017 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $15.7 million | $26.4 million |
| General and administrative expense | $5.3 million | $7.6 million |
| Total operating expenses / operating loss | $21.0 million | $34.1 million |
| Net loss | $21.1 million | $33.2 million |
| Net loss per share, basic and diluted | $0.59 | $0.95 |
| Cash used in operating activities | $16.5 million | $33.6 million |
| Cash and cash equivalents at year-end | $15.8 million | $31.8 million |
| Working capital | $14.1 million | $30.5 million |
- R&D and G&A expenses fell 40% and 31%, respectively. Management attributed the reduction principally to fewer clinical-trial and manufacturing activities, completion or close-out of large Phase III studies, and lower staffing and professional costs.
- Cash declined by $15.9 million during 2018. Financing provided $0.2 million, primarily from employee option exercises; there was no material equity offering during the year.
- Accumulated deficit was $237.7 million. The company had no product revenue and reported losses in every reporting period since inception. Profitability and operating margins are not meaningful given the absence of revenue.
- Year-end current liabilities were $2.9 million and total liabilities were $2.9 million; the balance sheet shows no debt borrowings. The company reported total shareholders’ equity of $41.4 million.
- Q4 2018 net loss was $6.1 million, or $0.17 per share, compared with a $7.2 million loss, or $0.20 per share, in Q4 2017.
Business developments and changes
- In 2018, XBiotech completed consolidation into its company-owned, 33,000-square-foot Austin facility, combining manufacturing, research and development, and administrative operations. Management said consolidation reduced operating costs. The facility passed a GMP audit by Eurofins Amatsigroup in December 2018.
- Phase II bermekimab studies in atopic dermatitis and hidradenitis suppurativa (HS) completed enrollment and reported topline results. In the open-label atopic dermatitis study, 71% of the 400 mg weekly cohort had at least a 75% EASI reduction after seven weeks. In the 42-patient HS study, HiSCR response rates at week 12 were 63% among patients previously failing anti-TNF therapy and 61% among those without prior anti-TNF treatment. These findings are from small, open-label studies and do not establish efficacy or approval.
- A bermekimab Phase I combination study in advanced pancreatic cancer had enrolled nearly all 16 planned patients. The company also continued work on antibody candidate 514G3, preclinical infectious-disease programs, and licensed the NY-ESO-1 antibody 12D7 in April 2018.
- The company reported increased syringe-production capacity as a 2019 objective, including a planned four-fold increase per drug-product lot by Q3 2019.
- Bermekimab’s European application for advanced colorectal cancer had received a negative CHMP opinion in 2017, upheld on re-examination; a second Phase III metastatic colorectal cancer study was discontinued in 2017 after an interim analysis. No marketing applications were under review at year-end.
Outlook, risks and unusual items
- Management expects significant operating losses to continue and says future spending will depend on pipeline progress and clinical plans. It stated that year-end cash was expected to fund operations through one year after the report date and to reach several potential milestones; the filing also identifies funding needs and the possibility of additional financing. There is no revenue or earnings guidance.
- Key risks include clinical or regulatory failure, inability to raise capital on acceptable terms, competition, manufacturing scale-up and validation, reimbursement and commercialization challenges, and dependence on key personnel. The company has no approved products and may never become profitable.
- Cash used in operations fell substantially versus 2017, but cash on hand also fell by about half. The company will require future financing if its cash needs exceed available resources; equity financing could dilute shareholders.
- Foreign-exchange movements produced a $0.5 million loss in 2018, versus a $0.6 million gain in 2017. Management described market risk from financial instruments, interest rates and currencies as not material and reported no hedging activity.
- A securities class action and two related federal cases were dismissed; the filing states no litigation remained. Management reported effective disclosure controls and internal control over financial reporting. The external auditor did not audit internal controls.
- No cash dividends have been paid, and the company does not expect to pay them in the foreseeable future.
Most important facts to verify
- Confirm cash runway against the latest cash balance, actual burn rate, and any subsequent financing or spending changes.
- Review the full clinical data and study designs for bermekimab, especially the limitations of the open-label Phase II dermatology studies and plans for later-stage trials.
- Check regulatory strategy following the EMA’s negative colorectal-cancer opinion and the discontinued Phase III study.
- Assess the Austin facility’s readiness, commercial-scale validation requirements, and whether planned manufacturing capacity increases were achieved.
- Resolve a balance-sheet presentation inconsistency in the filing: the consolidated balance sheet reports total assets of $44.545 million, while selected financial data reports $44.345 million; total liabilities and equity are reported as $44.345 million.